HMBS: A Potential Drug Target and Biomarker for Uroporphyrinogen I Synthesis

Target Name: HMBS

NCBI ID: G3145

HMBS

HMBS: A Potential Drug Target and Biomarker for Uroporphyrinogen I Synthesis

Uroporphyrinogen (UP)I synthesis is a critical step in the production of many important metabolites, including uroporphyrinogen decarboxylase (UD), which is involved in the metabolism of uroporphyrinogen to its final product, uroporphyrinogenogen decarboxylase (UD), which is a key enzyme in the uroporphyrinogen pathway. The regulation of UP synthesis is crucial for the development and progression of many diseases, including cardiovascular, neurodegenerative, and malignant diseases.

HMBS, or uroporphyrinogen synthase, is a key enzyme involved in the production of uroporphyrinogen from the amino acid cysteine. It is a small molecule protein that plays a vital role in the production of uroporphyrinogen, which is then further processed to form UD. The activity of HMBS is highly regulated, and it has been shown to play a crucial role in the regulation of cell growth, apoptosis, and inflammation.

Drug Target Potential

HMBS has been identified as a potential drug target due to its unique structure and its involvement in the production of uroporphyrinogen, which is a key metabolite involved in the development of many diseases. The production of uroporphyrinogen is a critical step in the production of many important metabolites, including UD, which is involved in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

HMBS is a protein that is expressed in a variety of tissues and cells, including the liver, lung, heart, and brain. It is highly regulated and has been shown to play a critical role in the regulation of cell growth and apoptosis.

The ability to target HMBS and modulate its activity has been shown to be an effective way to treat a variety of diseases, including neurodegenerative diseases, cancer, and cardiovascular diseases.

Biomarker Potential

HMBS has also been identified as a potential biomarker for several diseases, including neurodegenerative diseases, cancer, and cardiovascular diseases. The production of uroporphyrinogen is a critical step in the production of many important metabolites, including UD, which is involved in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.

The levels of HMBS have been shown to be elevated in the brains of individuals with neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Additionally, the levels of HMBS have been shown to be elevated in the livers of individuals with cancer.

Conclusion

In conclusion, HMBS is a protein that plays a critical role in the production of uroporphyrinogen and has been identified as a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand the regulation of HMBS activity and its potential as a drug target and biomarker.

Protein Name: Hydroxymethylbilane Synthase

Functions: As part of the heme biosynthetic pathway, catalyzes the sequential polymerization of four molecules of porphobilinogen to form hydroxymethylbilane, also known as preuroporphyrinogen (PubMed:18936296, PubMed:19138865, PubMed:23815679). Catalysis begins with the assembly of the dipyrromethane cofactor by the apoenzyme from two molecules of porphobilinogen or from preuroporphyrinogen. The covalently linked cofactor acts as a primer, around which the tetrapyrrole product is assembled. In the last step of catalysis, the product, preuroporphyrinogen, is released, leaving the cofactor bound to the holodeaminase intact (PubMed:18936296)

The "HMBS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HMBS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets